Research
Hormonal
Short sleep duration (less than 6 hours per night) is associated with increased body mass index (BMI) and obesity risk, with a stronger and more consistent association observed in children and young adults compared to older adults.
Prioritize getting at least 7-8 hours of sleep per night. If you are struggling with weight management, especially if you are younger, insufficient sleep may be driving your hunger hormones (ghrelin/leptin) to increase appetite and cravings. Consistent sleep duration is as important for weight control as diet and exercise.
GoodSupportsHIGH confidence
Epidemiological studies suggest that sleeping for less than 6 h is associated with increased morbidity in terms of development of obesity, type 2 diabetes, cardiovascular disease, and risk of accidents (14). ... In children, the pooled OR for short duration of sleep (< 10 hours) and obesity (BMI ≥ 95th percentile) was 1.89 (1.43 – 1.68; P < 0.0001). In adults, the pooled OR was 1.55 (1.43 – 1.68; P < 0.0001).
Why this rating
Based on multiple meta-analyses and longitudinal studies, though observational nature limits causal certainty.
Source
Sleep debt and obesity
Virginie Bayon et al. · Annals of Medicine · 2014
DOI 10.3109/07853890.2014.931103
narrative_reviewCited 239×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sleep restriction (4-5 hours per night) causes hormonal changes characterized by decreased leptin and increased ghrelin, leading to increased hunger, appetite, and a preference for high-carbohydrate and high-fat foods.Strong
- Sleep restriction (4-5 hours per night) impairs glucose tolerance and insulin sensitivity, increasing the risk of type 2 diabetes and metabolic disorders.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →